Virtu Financial LLC Avrobio, Inc. Transaction History

Virtu Financial LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 26, 2024	SELL	$1.22 - $1.62 $31,478 - $41,799	-25,802 Reduced 71.97%	10,048 $14,000
Q3 2023 Nov 14, 2023	BUY	$0.98 - $1.62 $13,032 - $21,542	13,298 Added 58.97%	35,850 $55,000
Q2 2023 Jul 27, 2023	SELL	$0.58 - $1.31 $10,304 - $23,274	-17,767 Reduced 44.07%	22,552 $21,000
Q1 2023 May 01, 2023	BUY	$0.76 - $1.82 $30,642 - $73,380	40,319 New	40,319 $40,000
Q3 2021 Nov 12, 2021	SELL	$5.53 - $9.28 $105,407 - $176,886	-19,061 Closed	0 $0
Q2 2021 Sep 17, 2021	BUY	$7.84 - $12.6 $149,438 - $240,168	19,061 New	19,061 $169,000
Q3 2020 Dec 11, 2020	SELL	$12.99 - $19.41 $130,705 - $195,303	-10,062 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$12.19 - $22.96 $122,655 - $231,023	10,062 New	10,062 $176,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.